CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming.
CordenPharma, a CDMO in innovative APIs and other products, have announced that they have joined the Science Based Targets initiative (SBTi).
The initiative helps companies to reduce emissions across the business. The aims are in line with those of the Paris Agreement; limiting the global temperature increase to 1.5 °C, to halve emissions before 2030 and achieve Net Zero by 2050. CordenPharma will be submitting their own specific targets to reduce emissions across the company as part of this agreement.
The SBTi is an independent body that assess and approves companies targets according to criteria they have set out to achieve those aims featured by the Paris agreement. It supports those companies in the private sector to give the best attempt at tackling climate change. The initiative was an idea born of the collaboration between the Committee for Development Policy (CDP), the United Nations Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).
Dr Michael Quirmbach, CEO & President of CordenPharma, commented: “Environmental, Social & Governance (ESG) is a top priority of both CordenPharma and our new private equity shareholders, Astorg. We are already working with companies such as Ecovadis on achieving the highest level of sustainability ratings for our facilities.
It is our responsibility as a leading CDMO to join the Science Based Targets initiative, as it represents a powerful opportunity to demonstrate to our customers how CordenPharma contributes towards the global transformation to a low-carbon economy. We know our customers put a lot of emphasis on ESG, so they look for that in a supplier. The validation and approval from the SBTi will give them visibility into understanding our reduction targets and processes to reduce carbon footprint throughout our organization at every level.”
Judith Charpentier, Partner, Head of Healthcare Investing at Astorg stated: “At Astorg ESG is a key part of sustainable value creation in our companies. As part of its ESG agenda, CordenPharma is making today a strong commitment to reduce its carbon emissions by joining the SBTi. Astorg will fully support the company on this journey.”
CordenPharma are adopting a company-wide collaborative approach by including all employees in implementing the action plan once approved by SBTi. By encouraging all areas of the company to be involved they hope to have greater success in achieving their targets for a Net Zero future as part of the initiative, as well as serving to educate and support all of the communities they impact.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance